Trial Profile
A Study Comparing the Cardiovascular (CV) Safety Associated with the Use of Canagliflozin Versus Other Non-Gliflozin Antidiabetic Agents in Type 2 Diabetes Mellitus (T2DM) Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jul 2017
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Dipeptidyl peptidase 4 inhibitors; Glucagon like peptide 1 receptor agonists; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 18 Jul 2017 New trial record
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.